Supplementary material

- Figure 1 Currently registered clinical trials
- Figure 2 MEDLINE search strategy
- Figure 3 Funnel plots for tocilizumab outcomes
- Figure 4 All agents forest plot for ordinal outcomes
- Figure 5 All agents forest plot for mean duration of hospitalisation
- Figure 6 All agents forest plot for mortality adjusted hazard ratios
- Figure 7 All agents forest plot for mortality risk ratios
- Figure 8 Funnel plots for all agent outcomes
- Table 1 Characteristics of included studies
- Table 2 Patient characteristics and study outcomes
- Table 3 GRADE rating
- Table 4 Meta-regression values
- Table 5(a-c) Risk of bias assessments

Estimated completion date (quarter)

Clinical Trial No.	Date	Sample size		2020				21				22	
			Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
NCT04315480	May-20	38			-								
NCT04310228	May-20	150			-								
ChiCTR2000029765	May-20	188											
NCT04322188	May-20	50			-								
NCT04329650	May-20	100											
NCT04306705	May-20	120											
NCT04346355	May-20	398 †											
ChiCTR2000030196	May-20	60											
NCT04359667	Jun-20	30											
NCT04492501	Jul-20	600											
NCT04357860	Jul-20	120											
NCT04335305	Aug-20	24											
NCT04363736	Aug-20	100											
NCT04320615	Aug-20	450 ‡											
NCT04366232	Aug-20	54											
NCT04327388	Aug-20	421											
NCT04519385	Aug-20	69										i	
NCT04435717	Aug-20	78										1	
NCT04445272	Aug-20	500											
NCT04315298	Aug-20	1912										<u> </u>	
NCT04462757	Sep-20	5											
NCT04364009	Sep-20	240											
NCT04372186	Sep-20	379											
NCT04335071	Oct-20	100											
NCT04345445	Oct-20	310											
NCT04356937	Oct-20	300											
NCT04332094	Oct-20	276											
NCT04361032	Oct-20	260											
NCT04560205	Oct-20	50											
NCT04377503	Dec-20	40											
NCT04409262	Dec-20	450											
NCT04386239	Dec-20	40											
NCT04330638	Dec-20	342*											
NCT04324021	Dec-20	54											
NCT04357808	Dec-20	30											
NCT04341584	Dec-20	240											
NCT04412291	Feb-21	120 *											
NCT04331795	Mar-21	332 ‡											
NCT04362111	Mar-21	30											
NCT04332913	Mar-21	30											
NCT04443881	Mar-21	180			-								
NCT04479358	Mar-21	332											
NCT04377750	May-21	500											
NCT04377659	May-21	40											
NCT04423042	Jun-21	30											
NCT04322773	Jun-21	200*											
NCT04486521	Jul-21	11000 *											
NCT04403685	Jul-21	129 †				ſ					ſ	Γ	
NCT04363853	Aug-21	200								ľ			
NCT04364009	Sep-21	240											
NCT04324073	Dec-21	239		1		1					1	1	
NCT04331808	Dec-21	228		1		1					1	1	
NCT04476979	Dec-21	120				l					l	1	
NCT04412772	Dec-21	300										1	
NCT04339712	Apr-22	40*				-							
NCT04359901	Apr-22	120											
NCT04357366	Apr-22 Apr-22	120		-									
NCT04337388	Apr-22 Apr-22	217	+	<u> </u>									
NCT04361552 NCT04424056	May-22 Nov-22	180 † 216 *											
			1			1	1	1	1	1	1	1	

Tocilizumab
Siltuximab
Sarilumab
Anakinra

Supplementary Figure 1. Currently registered clinical trials with estimated completion date presented per calendar year quarter. Clinical trials are stratified as per colour key. * same study investigating multiple immunomodulatory agents. † study has been terminated. ‡ results available

(last search 5th Oct)

- 1. Respiratory Distress Syndrome, Adult/
- 2. SARS Virus/
- 3. Severe Acute Respiratory Syndrome/
- 4. severe acute respiratory distress


syndrome*.mp.

- 5. Coronavirus Infections/
- 6. Coronavirus/
- 7. coronav*.mp.
- 8. covid*.mp.
- 9. SARS.mp.
- 10. Middle East Respiratory Syndrome

Coronavirus/

- 11. MERS.mp.
- 12. anakinra.mp.
- 13. kineret.mp.
- 14. tocilizumab.mp.
- 15. altizumab.mp.
- 16. actemra.mp.
- 17. roactemra.mp.
- 18. sarilumab.mp.
- 19. kevzara.mp.
- 20. siltuximab.mp.
- 21. sylvant.mp.
- 22. Interleukin 1 Receptor Antagonist
- Protein/
- 23. anti-IL6.mp.
- 24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 $\,$
- or 10 or 11
- 25. 12 or 13 or 14 or 15 or 16 or 17 or 18
- or 19 or 20 or 21 or 22 or 23
- 26. 24 and 25

Supplementary Figure 2. MEDLINE search strategy (last carried out on 23rd October 2020



Supplementary Figure 3: Funnel plots for outcomes evaluated in tocilizumab meta-analysis. A: ordinal outcomes, B: duration of hospitalisation, C: mortality (adjusted hazard ratio), D: mortality (risk ratio). Funnel plots presented separately for retrospective and prospective studies were applicable. Publication bias assessed using Egger's test, and p values presented next to funnel plot.

Author	Year	Drug			GenOR (95% CI)	% Weight	Intervention/Total	Day
Retrospective								
Kewan	2020	т –			0.83 (0.69, 1.01)	10.44	28/51	14
Potere	2020	т		•	1.94 (1.18, 3.19)	6.37	10/20	14
Somers	2020	т	+		1.48 (1.39, 1.58)	11.55	78/154	14
Cauchois	2020	А		\longrightarrow	4.00 (2.39, 6.69)	6.19	12/22	15
Cavalli	2020	А		_	1.50 (1.20, 1.88)	9.98	29/45	21
Rodriguez-Bano	2020	т	٠		1.17 (1.14, 1.20)	11.67	88/432	21
Capra	2020	т		-	2.29 (2.00, 2.62)	11.03	62/85	28
*Hill	2020	т			1.09 (0.98, 1.22)	11.25	43/88	28
Zheng	2020	т	•		0.84 (0.80, 0.89)	11.59	92/181	28
Eimer	2020	т			2.25 (1.79, 2.83)	9.93	22/44	30
Subtotal (I-square	ed = 97.6	6%, p = 0.000)		>	1.46 (1.21, 1.75)	100.00		
Prospective								
Albertini	2020	т			0.99 (0.80, 1.23)	9.61	22/44	14
#Hermine	2020	т	-		1.18 (1.10, 1.27)	24.23	63/130	14
#Salvarani	2020	т	+		0.97 (0.90, 1.05)	23.70	60/123	14
Della-Torre	2020	S	•		1.07 (0.90, 1.27)	13.00	28/56	28
#*Rosas	2020	т	•		1.15 (1.13, 1.18)	29.47	286/430	28
Subtotal (I-square	ed = 79.5	ó%, p = 0.001)	\diamond		1.09 (1.00, 1.18)	100.00		
NOTE: Weights ar	e from ra	andom effects ar	nalysis					
		I						
		.5	1	4	ļ.			

Supplementary Figure 4 – All agents. Generalised odds ratios (OR) for ordinal outcome forest plot. Generalised OR shown for each study with 95% confidence interval and day at which ordinal outcome recorded. Sample sizes given for patients receiving intervention (n) alongside total included (N) in study. Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, A = anakinra, S = sarilumab

* non peer-reviewed preprint studies

randomised controlled trials

A	Author	Year	Drug							Mean Days (95% Cl)	% Weight	n/N
_	Retrospective Eimer Klopfenstein Kewan Capra Somers Gokhale Zheng Rojas-Marte Subtotal (I-so	2020 2020 2020 2020 2020 2020 2020 202	T T T T T T 96.5%	5, p = 0.000)		*	*			24.14 (19.18, 29.10) 18.68 (14.21, 23.15) 19.86 (8.77, 30.95) 12.24 (11.51, 12.97) 28.26 (22.85, 33.67) 20.39 (15.72, 25.06) 27.50 (25.08, 29.92) 14.50 (12.74, 16.26) 20.55 (15.62, 25.48)	12.42 12.72 8.26 14.17 12.13 12.60 13.74 13.96 100.00	22/44 20/45 28/51 62/85 78/154 70/161 92/181 96/193
	Prospective Gremese Della-Torre "Gritti Sinha #"Rosas Subtotal (I-so NOTE: Weigh	2020 2020 2020 2020 2020 2020 uared =	Sa Si Sa T 97.5%	o, p = 0.000)	nalysis	*	*			14.55 (11.47, 17.63) 16.18 (11.04, 21.32) 21.57 (19.43, 23.71) 12.90 (11.70, 14.10) 22.32 (21.38, 23.26) 17.58 (12.59, 22.56)	19.75 17.40 20.55 21.10 21.20 100.00	53/53 28/56 30/60 255/255 294/438
-			1		7	14	21	28	35			

в

Author	Year	Drug				Mean Diff. (95% CI)	% Weight	n/N
Retrospective								
Eimer	2020	т		<u> </u>		-0.70 (-1.31, -0.09)	10.67	22/44
Klopfenstein	2020	т			•	0.50 (-0.10, 1.10)	10.80	20/45
Kewan	2020	т				0.39 (-0.17, 0.95)	11.23	28/51
Capra	2020	т			_	0.16 (-0.32, 0.64)	12.07	62/85
Somers	2020	т				0.35 (0.03, 0.67)	13.70	78/154
Gokhale	2020	т			_	0.34 (0.03, 0.66)	13.75	70/161
Zheng	2020	т				1.07 (0.75, 1.38)	13.77	92/181
Rojas-Marte	2020	т				-0.20 (-0.49, 0.08)	14.02	96/193
Subtotal (I-sq	uared =	85.0%, p = 0.00	D)		>	0.26 (-0.10, 0.62)	100.00	
Prospective								
Della-Torre	2020	Sa			-	0.02 (-0.51, 0.54)	100.00	28/56
Subtotal (I-sq	uared =	.%, p = .)		$ \rightarrow $	-	0.02 (-0.51, 0.54)	100.00	
NOTE: Weigh	ts are fro	m random effec	ts analysis					
		-2	-1	0	1	2		

Supplementary Figure 5 – All studies mean duration of hospitalisation (days) forest plot. **A**: Mean duration of hospital stay. **B**: Mean difference compared with controls in duration of hospital stay. Effect sizes and associated 95% confidence intervals presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, S = sarilumab, Si = siltuximab.

* non peer-reviewed preprint studies

randomised controlled trials

Author	Year	Drug		a	HR (95% CI)	% Weight	n/N	Day
Retrospective								
*Martinez-Sanz	2020	т	+	1	.53 (1.20, 1.96)	9.90	260/1229	6
*Ramaswamy	2020	т —	•	0	.25 (0.07, 0.90)	3.58	21/86	7
Guaraldi	2020	т		0	.38 (0.17, 0.83)	6.04	179/544	14
Rodriguez-Bano	2020	т —	•	0	.12 (0.02, 0.56)	2.44	88/432	21
Biran	2020	т	+	0	.64 (0.47, 0.87)	9.53	210/630	22
Gupta	2020	Т	+	0	.71 (0.56, 0.92)	9.88	433/3925	27
Somers	2020	т	-	0	.55 (0.33, 0.90)	8.14	78/154	28
*Hill	2020	Т		0	.57 (0.21, 1.52)	4.86	43/88	28
De Rossi	2020	т 🗕	-	0	.06 (0.02, 0.19)	4.20	90/158	30
lp	2020	Т	+	0	.76 (0.57, 1.00)	9.69	134/547	30
Eimer	2020	т		0	.52 (0.19, 1.39)	4.84	22/44	30
Canziani	2020	Т		0	.82 (0.42, 1.58)	6.94	64/128	30
Gokhale	2020	Т		0	.62 (0.38, 0.99)	8.32	70/161	31
*Narain	2020	Т		0	.72 (0.40, 1.28)	7.54	60/1565	NR
*Narain	2020	Α		0	.40 (0.13, 1.28)	4.12	37/1505	NR
Subtotal (I-squar	red = 79	9.2%, p = 0.000)	\diamond	0	.57 (0.42, 0.77)	100.00		
Prospective			_					
#Hermine	2020	Т	- • <u>-</u>		.58 (0.24, 1.40)	21.36	63/130	14
#Stone	2020	Т	•		.52 (0.41, 5.61)		161/243	28
Della-Torre	2020	Sa -	•		.36 (0.08, 1.68)		28/56	28
*Gritti	2020	Si	•		.46 (0.22, 0.97)		30/60	30
Mikulska	2020	Т	•		.48 (0.23, 0.99)	31.34	29/95	30
Subtotal (I-squar	red = 0.	0%, p = 0.561)	\diamond	0	.54 (0.36, 0.81)	100.00		
NOTE: Weights a	are from	n random effects	analysis					
		.01	1	10				

Supplementary Figure 6 – All studies, adjusted hazard ratios (HR) for overall mortality forest plot. Adjusted HRs with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included (N) in study. Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, A = anakinra, S = sarilumab, Si = siltuximab.

 $\ensuremath{^*}$ non peer-reviewed preprint studies

randomised controlled trials

NR, not reported


Author	Year	Drug	RR (95% CI)	% Weight	n/N	Da
id in or	.ou.	Didg	1	moight		Du
Retrospective						
*Martinez-Sanz	2020	т	 1.89 (1.44, 2.50) 	5.52	260/1229	6
*Ramaswamy	2020	т	1.14 (0.33, 3.92)	2.05	21/85	7
Patel	2020	т	0.80 (0.36, 1.77)	3.34	42/83	7
*Roumier	2020	т —	0.32 (0.09, 1.10)	2.07	30/59	8
Capra	2020	т 🗕	0.07 (0.02, 0.29)	1.61	62/85	9
Guaraldi	2020	т 🚽	0.31 (0.16, 0.60)	3.81	179/544	14
*Carvalho	2020	т	1.03 (0.30, 3.53)	2.06	29/53	14
Kewan	2020	т –	1.23 (0.22, 6.88)	1.26	28/51	14
*Ruiz-Antoran	2020	т	 0.53 (0.38, 0.75) 	5.29	268/506	18
Cavalli	2020	а 🗕	0.24 (0.07, 0.84)	1.98	29/45	21
Rodriguez-Bano	2020	т 🗕	0.19 (0.05, 0.77)	1.73	88/432	21
Biran	2020	Т	 0.80 (0.67, 0.94) 	5.85	210/630	22
Gupta	2020	т	 0.71 (0.61, 0.83) 	5.88	433/3925	27
•Hill	2020	т	• 0.63 (0.30, 1.31)	3.56	43/88	28
Somers	2020	т .	0.49 (0.27, 0.87)	4.24	78/154	28
De Rossi	2020	т —	0.16 (0.07, 0.34)	3.45	90/158	30
Canziani	2020	Ť	• 0.71 (0.41, 1.22)	4.40	64/128	30
Eimer	2020	Ť -	• 0.71 (0.26, 1.98)	2.58	22/44	30
Gokhale	2020	T		5.37	70/161	31
Pettit	2020	T	1.71 (1.01, 2.89)	4.46	74/148	NF
Guisado-Vasco	2020	T		5.43	132/607	NE
*Wadud	2020	т	• 0.74 (0.45, 1.22)	4.61	44/94	NE
*Tsai	2020	Ť	 ↓ 0.74 (0.45, 1.22) ↓ 1.00 (0.56, 1.79) 	4.01	66/132	NF
Rojas-Marte	2020	T	◆ 0.79 (0.58, 1.08)	5.38	96/193	NB
Roomi	2020	T	2.08 (0.86, 5.04)	3.01	32/176	NE
	2020	т́ —		2.98	20/45	NB
Klopfenstein	2020	т — т	0.52 (0.21, 1.28)		20/45 54/111	
*Kimmig Subtatal (Laguard			1.82 (0.94, 3.54)	3.86	54/111	NB
Subtotal (I-square	a = 81.0%	, p = 0.000)	0.74 (0.59, 0.91)	100.00		
Prospective						
Albertini	2020	т — 🔶	0.10 (0.01, 0.66)	10.35	22/64	14
#Hermine	2020	т	1.24 (0.44, 3.52)	24.72	63/130	14
#Salvarani	2020	т —	1.05 (0.07, 16.27)	5.70	60/123	14
*Della-Torre	2020	si —	0.40 (0.08, 1.92)	14.44	28/56	28
#Stone	2020	T	1.44 (0.40, 5.21)	19.14	156/231	28
Mikulska	2020	÷ 4	• 0.57 (0.21, 1.56)	25.66	29/95	30
Subtotal (I-square			0.67 (0.34, 1.34)	100.00	20.00	00
NOTE: Weights ar	e from ran	dom effects analysis				
		.01	1 10 20			

Supplementary Figure 7 – All agents, mortality risk ratios (RR) forest plot. Risk ratios with associated 95% confidence interval and day of censorship presented for each study. Sample sizes given for patients receiving intervention (n) and total included in study (N). Summary estimates presented separately for prospective and retrospective studies. Drugs labelled where T = tocilizumab, A = anakinra, Si = siltuximab.

* non peer-reviewed preprint studies

randomised controlled trials

NR, not reported



Supplementary Figure 8: Funnel plots for outcomes evaluated in meta-analysis of all agents. A: ordinal outcomes, B: duration of hospitalisation, C: mortality (adjusted hazard ratio), D: mortality (risk ratio). Funnel plots presented separately for retrospective and prospective studies were applicable. Publication bias assessed using Egger's test, and p values presented next to funnel plot.

Author, year	Study country	Centre	Study design	Dose	Participant criteria	Outcomes reported	Concomitant therapies
ANAKINRA							
Aouba, 2020	France	single centre	Prospective	100mg S/C 12hourly D1-D3, 100mg/24 hours D4-10	Hospitalised, oxygen flow <6L/min, CRP>50mg/L	CRP, oxygen dose and duration of therapy	N/R
Huet, 2020	France	single centre	Prospective with control	100mg S/C twice daily for 72h, then 100mg daily for 7 days	Respiratory failure, bilateral lung infiltrates	mortality, ventilatory requirement, laboratory biomarkers	hydroxychloroquine, antibiotics, IV methylprednisolone
Cauchois, 2020	France	multi- centre	Case-control	300mg IV daily for 5 days then tapered over 3 days	respiratory failure and CRP > 110mg/L	ventilatory requirement, laboratory biomarkers	hydroxychloroquine, antibiotics
Cavalli, 2020	Italy	single centre	Case-control	10mg/kg/day IV	Mod-severe ARDS requiring CPAP and hyperinflammation	Survival, ventilatory requirement, CRP	CPAP, hydroxychloroquine, lopinavir, ritonavir
*Narain, 2020	USA	multi- centre	Case-control	N/R	hyperinflammation	hospital mortality	hydroxychloroquine
SARILUMAB							
Benucci, 2020	Italy	single centre	Prospective	400mg IV repeated twice at 200mg at 48 hourly intervals	N/R	ventilatory requirement, laboratory biomarkers	hydroxychloroquine, azithromycin, antivirals
Della-Torre, 2020	Italy	single centre	Prospective with control	400mg IV	radiological bilateral lung infiltrates and hyperinflammation	overall survival, ventilatory requirements	hydroxychloroquine, azithromycin, antivirals
Gremese, 2020	Italy	single centre	Prospective	400mg IV	respiratory failure and radiological infiltrates	ventilatory requirement, discharge from ICU, mortality	hydroxychloroquine, azithromycin, antivirals
Sinha, 2020	USA	single centre	Prospective	200mg IV	respiratory failure and hyperinflammation	mortality, discharge from hospital, IMV	hydroxychloroquine, azithromycin
SILTUXIMAB							
*Gritti 2020	Italy	single centre	Prospective with control	11mg/kg IV. Second dose 72 hours later (n=6)	respiratory failure requiring IVM or non-IVM support	mortality, time to IVM, laboratory biomarkers	antivirals, hydroxychloroquine, corticosteroids
TOCILIZUMAB							

France	single centre	Prospective with control	8mg/kg IV. Second dose 72 hours later (n=20)	respiratory failure, bilateral radiological infiltrates, elevated CRP	respiratory rate, oxygen requirements, laboratory biomarkers	hydroxychloroquine and azithromycin
USA	multi- centre	Prospective	4mg/kg/day IV 12 hourly	supplemental oxygen dose >3L/min, but not mechanically ventilated	mortality, ventilatory requirement, laboratory biomarkers	methylprednisolone
Spain	single centre	Prospective	N/R	N/R	mortality	corticosteroids (98%)
Brazil	single centre	Prospective with control	400mg IV two doses	respiratory failure, hyperinflammation	in-hospital mortality, need for renal replacement therapy, inflammatory and oxygenation markers, use of antibiotics	hydroxychloroquine, azithromycin
Iran	single centre	Prospective	400mg IV	severe: respiratory failure, or bilateral radiological infiltrates, IL-6>10pg/mL critical: need for ICU or IMV	oxygen requirements, ventilatory requirements, death, laboratory biomarkers	antivirals
France	multi- centre	Open label RCT	8mg/kg IV	radiological infiltrates with respiratory failure but not admitted to ICU	dead or ventilatory support on day 4, survival at day 14, laboratory biomarkers	antivirals, corticosteroids
Iran	multi- centre	Prospective	324mg or 486mg SC (weight dependent)	respiratory failure and hyperinflammation	all-cause mortality, change on 6-point ordinal scale, laboratory biomarkers	hydroxychloroquine, antivirals, antibiotics, interferon beta
Italy	single centre	Prospective with control	8mg/kg IV (62%) or 162mg SC (38%). Second dose in 24%	respiratory failure	IMV, death	hydroxychloroquine, antivirals, antibiotics
Italy	single centre	Prospective	8mg/kg IV repeated after 12h	respiratory failure, IL-6 > 40pg/mL	death, hospital discharge	hydroxychloroquine, antivirals, antibiotics
Italy	multi- centre	Single arm, open- label phase 2	8mg/kg/IV	respiratory failure	mortality rates at 14 and 30 days	hydroxychloroquine, antibiotics, antivirals, steroids
USA	multi- centre	Placebo-controlled, double blind, phase 3 RCT	8mg/kg IV, second dose 8- 24h later permitted	respiratory failure with bilateral radiological infiltrates	clinical status on a 7-point ordinal scale, time to hospital/ICU discharge, time to improvement on	corticosteroids, antivirals, convalescent plasma
	USA Spain Brazil Iran France Iran Italy Italy Italy	FrancecentreUSAmulti-centreSpainsingle centreBrazilsingle centreIransingle centreIransingle centreIranmulti-centreIranmulti-centreItalysingle centreItalysingle centreItalysingle centreItalymulti-centreItalymulti-centreItalymulti-centreItalymulti-centreItalymulti-centreItalymulti-centreItalymulti-centreItalymulti-centre	Francecentrewith controlUSAmulti-centreProspectiveSpainsingle centreProspectiveBrazilsingle centreProspective with controlIransingle centreProspectiveFrancemulti- centreOpen label RCTIranmulti- centreProspectiveIransingle centreProspectiveIranmulti- centreProspectiveItalysingle centreProspective with controlItalysingle centreProspectiveItalymulti- centreSingle arm, open- label phase 2USAmulti- centrePlacebo-controlled, double blind,	Francecentrewith controlhours later (n=20)USAmulti-centreProspective4mg/kg/day IV 12 hourlySpainsingle centreProspectiveN/RBrazilsingle centreProspective with control400mg IV two dosesIransingle centreProspective with control400mg IV two dosesIransingle centreProspective with control400mg IVFrancemulti- centreOpen label RCT8mg/kg IVIranmulti- centreProspective with control324mg or 486mg SC (weight dependent)Italysingle centreProspective with control8mg/kg IV (62%) or 162mg SC (38%). Second dose in 24%Italysingle centreProspective Prospective8mg/kg IV repeated after 12hItalymulti- centreSingle arm, open- label phase 28mg/kg IV, second dose 8- 24h later nermitted	France single centre Prospective with control Brokential single centre Prospective Prospective Brokential single centre Prospective Prospective M/R Supplemental oxygen dose >3L/min, but not mechanically ventilated Spain single centre Prospective with control N/R N/R N/R Brazil single centre Prospective with control 400mg IV two doses respiratory failure, hyperinflammation Iran single centre Prospective with control 400mg IV severe: respiratory failure, hyperinflammation Iran single centre Prospective 400mg IV severe: respiratory failure, or bilateral radiological infiltrates, IL-6>10pg/mL critical: need for ICU or IMV France multi- centre Open label RCT 8mg/kg IV respiratory failure and hyperinflammation Iran multi- centre Prospective with centre 324mg or 486mg SC (weight dependent) respiratory failure and hyperinflammation Italy single centre Prospective with control 8mg/kg IV (62%) or 162mg SC (38%). Second dose in 24% respiratory failure, IL-6 > 40pg/mL Italy multi- centre Single arm, open- label phase 2 8mg/kg IV, repeated after 12h respiratory failure USA multi- centre Placebo-controlled, double blind, 8mg/kg IV, second dose 8- 24b later nermitted respiratory failure w	France centresingle with controlProspective hours later (n=20)radiological infiltrates, elevated CRPrequirements, laboratory biomarkersUSAmulti- centreProspective4mg/kg/day IV 12 hourlysupplemental oxygen dose supplemental oxygen dose >31/min, but not mechanically ventilatedmortality, ventilatory requirement, laboratory biomarkersSpaincentreProspectiveN/RN/Rmortality, ventilatory requirement, laboratory biomarkersBrazilsingle centreProspective400mg IV two dosesrespiratory failure, hyperinflammationin-hospital mortality, need for real replacement therapy, inflammatory and oxygen atomatory biomarkers, use of antibioticsIransingle centreProspective400mg IVsevere: respiratory failure, or bilateral radiological inflitrates, IL-S10pg/mLoxygen requirements, therapy, inflammatory and oxygen requirements, udatiory requirements, udatiory requirements, udatiory requirements, udatiory failure but not admitted to ICUoxygen requirements, dead or ventilatory biomarkersIranmulti- centreOpen label RCT8mg/kg IV (62%) or 162mg SC (38%). Second dose in 24%respiratory failure, respiratory failure, respiratory failure, ille-Single ammethal admitted to ICUIMV, deathItalysingle centreProspective with controlSmg/kg IV (62%) or 162mg 24%respiratory failure, respiratory failure, ille-Si 400g/mLIMV, deathItalysingle centreProspective with controlSmg/kg IV, second dose 8- 24%<

						ordinal scale, incidence of IMV	
Salvarani, 2020	Italy	multi- centre	Open label RCT	8mg/kg IV, repeated 12h later	respiratory failure and hyperinflammation	ICU admission and need for IMV, death, respiratory failure	hydroxychloroquine, antivirals, antibiotics
*Sanchez- Montalva, 2020	Spain	single centre	Prospective	400-600mg IV	respiratory failure, hyperinflammation	death at 7 days, admission to ICU, ARDS	Hydroxychloroquine, antibiotics, antivirals
Sciascia, 2020	Italy	multi- centre	Prospective	8mg/kg IV or 324mg S/C. Second dose in 83%	respiratory failure, hyperinflammation	medication safety, oxygen requirement, laboratory biomarkers	antivirals
*Strohbehn, 2020	USA	single centre	Phase 2 open label	40-200mg	bilateral radiological infiltrates, fever, CRP>40mg/L	resolution of fever, CRP reduction, overall survival at 28 days, rate and duration of IMV, duration of supplemental oxygen	hydroxychloroquine, azithromycin, antiviral
Toniati, 2020	Italy	single centre	Prospective	8mg/kg IV, repeated after 12h (87%). Third dose 24h later (13%)	respiratory failure requiring ventilatory support	ventilatory requirements, discharge, death	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Biran, 2020	USA	multi- centre	Case-control	400mg IV with 12% receiving a second dose	hospitalised requiring ICU stay	mortality, inflammatory biomarkers, oxygenation, infection, use of vasopressors	corticosteroids, hydroxychloroquine, azithromycin
Canziani, 2020	Italy	multi- centre	Case-control	8mg/kg IV followed by a second dose 24h later (95%)	respiratory failure, elevated CRP, absence of active bacterial infection	mortality, incidence of invasive ventilation, thromboembolic events, haemorrhagic event, infections	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Capra, 2020	Italy	single centre	Case-control	400mg IV (53%); 324mg SC (44%)	tachypnoea or hypoxia. IMV patients excluded	overall mortality	hydroxychloroquine, antivirals
De Rossi, 2020	Italy	single centre	Case-control	400mg IV (48%); 324mg SC (52%)	respiratory failure, bilateral radiological infiltrates. IMV patients excluded	overall mortality	hydroxychloroquine, antivirals

Eimer, 2020	Sweden	single centre	Case-control	8mg/kg IV	respiratory failure admitted to intensive care, with hyperinflammation	30-day mortality, time to extubation, number of ventilator free-days, length of hospital and ICU stay	Nil
Galvan Roman, 2020	Spain	single centre	Case-control	8mg/kg/IV, repeated after 12h	respiratory failure, hyperinflammation,	mortality, IL-6 levels, mechanical ventilation,	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Garcia, 2020	Spain	single centre	Case-control	400-600mg IV repeated 12h apart with up to 3 doses	radiological infiltrates, respiratory failure and hyperinflammation	ICU admission and need for IMV	hydroxychloroquine, antivirals, azithromycin
Gokhale, 2020	India	single centre	Case-control	400mg IV	respiratory failure, bilateral radiological infiltrates, hyperinflammation	overall mortality	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Guaraldi, 2020	Italy	multi- centre	Case-control	8mg/kg IV, repeated after 12h, or 324mg SC single dose	respiratory failure, lung infiltrates >50%	IMV or death	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Guisado- Vasco, 2020	Spain	single centre	Case-control	8mg/kg/IV	radiological infiltrates and respiratory failure	hospital mortality, length of hospitalisation, admission to ICU, requirement for IMV	hydroxychloroquine, antivirals, corticosteroids
Gupta, 2020	USA	multi- centre	Case-control	Treated in first 2 days, dose not specified	Admitted to ICU	hospital mortality, secondary infections	hydroxychloroquine, azithromycin, corticosteroids
* Hill, 2020	USA	single centre	Case-control	400mg IV, repeated in 3 patients after 24h	fever with either respiratory failure, haemodynamic instability, or serum IL-6 >5 times upper limit of normal	clinical improvement (two- point reduction on six- point scale), mortality within 28 days	hydroxychloroquine, remdesivir
Holt, 2020	USA	single centre	Case-control	400mg IV	respiratory failure and hyperinflammation	mortality	N/R
lp, 2020	USA	multi- centre	Case-control	400mg IV	hospitalised on ICU	overall mortality	hydroxychloroquine, azithromycin, corticosteroids
Kewan, 2020	USA	single centre	Case-control	8mg/kg IV	respiratory failure, lung infiltrates, hyperinflammation	Time to clinical improvement, duration of IMV, duration of vasopressor support	hydroxychloroquine, azithromycin, corticosteroids

*Kimmig, 2020	USA	single centre	Case-control	400mg IV	clinical deterioration with hyperinflammation	mortality, infection rate	N/R
Klopfenstein, 2020	France	single centre	Case-control	N/R	respiratory failure, >25% lung infiltrates, hyperinflammation	death and/or ICU admission	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Martinez- Sanz, 2020	Spain	multi- centre	Case-control	600-800mg	hospitalised	time to death or intensive care unit admission	hydroxychloroquine, antivirals, antibiotics, corticosteroids
#*Narain, 2020	USA	multi- centre	Case-control	N/R	hyperinflammation	hospital mortality	hydroxychloroquine
Patel, 2020	USA	single centre	Case-control	N/R	Severe: respiratory failure Critical: requiring IMV	overall mortality, hospital discharge, inflammatory biomarkers	hydroxychloroquine, antivirals, corticosteroids
Pettit, 2020	USA	single centre	Case-control	400mg IV	respiratory failure with hyperinflammation	infection rate	hydroxychloroquine and remdesivir
Potere, 2020	Italy	single centre	Case-control	324mg SC	hyperinflammation with no hypoxaemia	disease progression, inflammatory biomarkers	hydroxychloroquine, antivirals, corticosteroids
*Ramaswamy, 2020	USA	multi- centre	Case-control	400mg IV, 8mg/kg	respiratory failure, hyperinflammation	inpatient mortality	hydroxychloroquine, azithromycin, corticosteroids
Rodriguez- Bano, 2020	Spain	multi- centre	Case-control	N/R	hyperinflammation. IMV patients excluded	intubation, death, secondary bacterial infections, scores on a seven-point ordinal scale	hydroxychloroquine, antivirals, antibiotics, interferon beta
Rojas-Marte, 2020	USA	single centre	Case-control	N/R	respiratory failure	overall mortality rate	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Roomi, 2020	USA	single centre	Case-control	N/R	hospitalised	overall mortality, IMV	hydroxychloroquine, corticosteroids
*Rossi, 2020	France	single centre	Case-control	400mg IV	respiratory failure. IMV patients excluded	composite of all-cause mortality and invasive ventilation	hydroxychloroquine, antivirals, corticosteroids
Rossotti, 2020	Italy	single centre	Case-control	8mg/kg IV repeated 12h later if ongoing fever	respiratory failure, bilateral radiological infiltrates, hyperinflammation	overall survival	hydroxychloroquine, antivirals

*Roumier, 2020	France	single centre	Case-control	8mg/kg IV repeated once	respiratory failure, hyperinflammation	mortality, IMV, hospital status	Hydroxychloroquine, azithromycin, corticosteroids
*Ruiz- Antoran, 2020	Spain	multi- centre	Case-control	400-600mg IV repeated up to three doses	respiratory failure, hyperinflammation	in-hospital mortality	hydroxychloroquine, antivirals, antibiotics, corticosteroids
Somers, 2020	USA	single centre	Case-control	8mg/kg IV	IMV	survival probability, 6- point ordinal scale at day 28	hydroxychloroquine, corticosteroids
Stone, 2020	USA	multi- centre	Double blind RCT	8mg/kg IV	hyperinflammation with two of: fever, lung infiltrates or respiratory failure	intubation or death,	antiviral, hydroxychloroquine, corticosteroids
*Tsai, 2020	USA	single centre	Case-control	400-800mg IV	respiratory failure and ferritin >300ug/mL	overall mortality	hydroxychloroquine, azithromycin
* Wadud, 2020	USA	single centre	Case-control	N/R	hospitalised	mortality, discharge, number of days on ventilator, in ICU and in hospital	N/R
Zheng, 2020	China	single centre	Case-control	400mg IV, repeat after 24h if persistent fever	severe: respiratory failure critical: shock	mortality, discharge, inflammatory biomarkers	Nil

Supplemental Table 1 – Methodological characteristics of included studies. Age in years reported as mean (standard deviation) unless otherwise stated.

ARDS, acute respiratory distress syndrome; CPAP, continuous positive airways pressure; CRP, C reactive protein; ICU, intensive care unit; IL6, interleukin 6; IV, intravenous; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; N/R, not reported; SC, subcutaneous; * non peer-reviewed preprint study; #, study investigating both anakinra and tocilizumab

Author, year	Study design	N Treatment/ Control	Follow up, days	Control Age	Intervention Age	Sex (male control) %	Sex (male) intervention %	Outcomes
						ANAKINRA		
Aouba, 2020	Prospective	9/0	11	-	58 (11)ª	-	89	CRP levels decreased and normalised in 5/8 patients at D11. All nine patients were alive
Huet, 2020	Prospective with control	52/44	N/R	71 (15) ª	71 (13) ª	57	69	IMV or death in anakinra group vs control HR 0.22; 95% CI 0.1-0.49. For death alone: HR 0·30; 95% CI 0·12–0·71. Decrease in CRP vs control group.

Cauchois, 2020	Prospective with control	12/10	N/R	N/R	N/R	N/R	N/R	Fewer no. days with oxygen < 3L/min in anakinra group vs control at day 20 (p<0.05). No. of days without IMV similar. Rapid reduction of CRP with anakinra vs. controls (p<0.001)
Cavalli, 2020	Prospective with control	29/16	21	70 (64-78) ^c	63 (51-73) °	88	83	Control: Survival at 21 days of 56%. Mechanical ventilation-free survival 50%. Tocilizumab high dose: Survival of 90% at 21 day (p=0.009 vs control group). IMV-free survival 72% (p=0.15 vs control group)
*# Narain, 2020	Prospective with control	37/1505	N/R	65 (54-77) ^c	67 (58-74) ^c	62	68	No effect on mortality (aHR 0.4; 95% CI 0.13-1.28)
					S	ARILUMAB		
Benucci, 2020	Prospective	8/0	14	-	62	-	75	87% discharged within 14 days.
Della-Torre, 2020	Prospective with control	28/28	28	57 (52-60) ^c	56 (49-60) ^c	71	85	Survival similar in both groups (HR 0.36; 95% CI 0.08-1.68). In treatment group, median time to death higher (19 vs. 4 days; p=0.006), median time to CRP normalisation lower (6 vs. 12 days; p<0.0001). Median time to clinical improvement, discharge and IMV free survival similar. Median time to clinical improvement shorter in patients with a baseline PaO2/FiO2 >100mgHg (7 vs 28 days; HR 0.18; 95% CI 0.02-0.26)
Gremese, 2020	Prospective	53/0	16 (14-24)♭	-	66 (40-95) ^c	-	89	83% (89.7% in medical wards and 64.3% in ICU) improved on therapy. Overall mortality of 5.7%
Sinha, 2020	Prospective	255/0	N/R	-	59 (47-70) °	-	63	10.9% of patients died. Mortality was lower in patients with FiO2 < 0.45 (HR 0.24; 95% CI 0.08-0.74)
					SI	LTUXIMAB		
* Gritti 2020	Prospective with control	30/30	33.3 (7-58) ^b	65 (56-70) ^b	64 (57-66) ^b	80	77	30-day mortality lower in treatment arm (HR 0.46; 95% CI 0.22-0.97). 53% recovered and were discharged.

					то	CILIZUMAB		
Albertini, 2020	Prospective with control	22/22	14	65 (41-82) ^b	64 (41-80) ^b	68	73	average respiratory rate at d14 lower in treated (21.5 vs 25.5 breaths/min; 95% CI -7.5 to -0.4). No difference in requirement for intubation. Significant fall in CRP in treated patients on d7 (p=0.04)
Antony, 2020	Prospective	80/0	N/R	-	63 (51-72) ^b	-	57	8.8% of patients died and 11.3% required mechanical ventilation. CRF levels reduced post therapy, whereas IL-6 increased
Campins, 2020	Prospective	58/0	N/R	-	60.6	-	72	32.4% of patients were admitted to intensive care, 13.8% died. No difference in median CRP and IL-6 between survivors and dead
* Carvalho, 2020	Prospective with control	29/24	14	59 (51-72)°	55 (44-65) °	75	62	Tocilizumab not associated with mortality (HR 3.97; 95% CI 0.28- 5.72), or positive cultures (OR 1.73; 95% CI 0.22-13.82)
Dastan, 2020	Prospective	42/0	28	-	56 (44-61) ^c	-	64	14% required IMV, remaining patients showed clinical improvement. By d28, 16.7% of patients died
Hermine, 2020	Open label RCT	63/67	90	63 (57-72) ^c	64 (57-74) ^c	66	70	At day 14, 12% (95% CI −28% to 4%) fewer patients died or needed ventilation compared with controls (aHR 0.58; 90% CI 0.30-1.09)
Malekzadeh, 2020	Prospective	126/0	14	-	54 (13) ª	-	64	By day 14, 4.7% (4/86) of severe patients and 50% (20/40) of critical patients died. By the end, 7% (6/86) of severe patients and 60% (24/40) of critical patients died.
Mikulska, 2020	Prospective with control	26/99	53 (4-70) ^b	68 (13) ª	66 (10) ^a	67	83	14-day mortality was 13.8% vs. 21.8% in control group. Mortality at study end lower in treatment group (HR 0.48; 95% CI 0.23-0.99)
Morena, 2020	Prospective	51/0	30	N/A	60 (50-70) ^c	N/A	78	Over a median follow up of 34 days, 67% of patients showed an improvement in clinical severity. Overall mortality rate was 27%
* Perrone 2020	Single-arm, open-label phase 2 trial	180/121	30	≤60: 36% 61-70: 33% ≥71: 31%	≤60: 44% 61-70: 37% ≥71: 19%	77	83	Pre-specified expected lethality rates defined as 20% and 35% at 14 and 30 days respectively. Lethality rates were 18.4% (95% CI 13.6- 24.0, p=0.52) and 22.4% (95% CI 17.2-28.3, p<0.001) at 14 and 30 days. In tocilizumab group alone, lethality rates were 15.6% and 20%.

* Rosas, 2020	Placebo- controlled, double phase 3 RCT	294/144	60	61 (14) ª	61	70	70	No improvement in clinical status at day 28 (p=0.36), or mortality. Ordinal scale values similar (OR 1.19; 95% CI 0.81-1.76). Median time to hospital discharge shorter with tocilizumab than placebo (20 and 28 days; HR 1.35 95% CI 1.02-1.79). Median duration of ICU stay shorter with tocilizumab (9.8 and 15.5 respectively, p=0.045). Median time to improvement from baseline in 2 or more categories on ordinal scale was 14 days (12-17) in tocilizumab arm and 18 (15-28) days in placebo (p=0.08). Incidence of IMV was 27.9% in tocilizumab arm and 36.7% in placebo (p=0.14)
Salvarani, 2020	Open label RCT	60/63	30	60 (54-69) ^c	62 (52-74) ^c	56	67	28% in the tocilizumab arm and 27% in SOC group showed clinical worsening within 14 days (RR, 1.05; 95% CI, 0.59-1.86). Mortality at 14 days and at 30 days (was comparable in the 2 groups
* Sanchez- Montalva, 2020	Prospective	82/0	N/R	-	59 (20) ª	-	63	Mortality at 7 days was 26.8%. ARDS developed in 54.9%
Sciascia, 2020	Prospective	63/0	14	-	63 (13) ^a	-	88	Tocilizumab associated with increased survival (HR 2.2; 95% CI 1.3- 6.7). Overall mortality was 11%
Stone, 2020	Double blind RCT	161/82	28	57 (45-70) ^c	62 (46-70) ^c	55	60	HR for intubation or death compared with placebo was 0.83;95% Cl, 0.38 to 1.81. At 14 days, 18.0% in tocilizumab and 14.9% in of placebo had disease progression. At 14 days, 24.6% of tocilizumab group and 21.2% of placebo were receiving supplemental oxygen.
* Strohbehn, 2020	Phase 2 open label trial with control	32/41	28	68 (58-78) ^c	69 (41-73) ^c	59	50	At 24 hours, 75% of tocilizumab vs 34.1% of control achieved resolution of fever (p=0.001). 86.2% of tocilizumab vs. 14.3% control achieved CRP decrease of at least 25% (p<0.001). Median time to recovery was 3 days (IQR 2-5)
Toniati, 2020	Prospective	100/0	10	-	62 (57-71) ^c	-	88	Overall at 10 days 77% of patients improved or stabilised and 23% worsened. Mortality was 20%
Biran, 2020	Case-control	210/420	22 (11-53) ^c	65 (56-74)°	62 (53-71) ^c	67	74	Exposure to tocilizumab was associated with lower hospital mortality (HR 0.64; 95% CI 0.47-0.87). In subgroup analyses, tocilizumab associated with decreased hospital mortality in those with a CRP≥150mg/L (HR 0.48;95% CI 0.3-0.77), but not in those with CRP>150mg/L (HR 0.92;95% CI 0.57-1.48).

Canziani, 2020	Case-control	64/64	N/R	64 (8) ª	63 (12) ª	73	73	30-day mortality unaffected (aHR 0.82; 95% CI 0.42-1.58). Between days 6 and 30, HR 0.41 (95% CI 0.17-0.96) for tocilizumab vs controls. Tocilizumab associated with lower risk of IMV (HR 0.36; 95% CI 0.16- 0.83). No effect on thrombotic events, bleeding, infection
Capra, 2020	Case-control	62/23	28	70 (55-80) ^c	63 (54-73) ^c	83	73	Tocilizumab associated with reduced risk of mortality (HR 0.035; 95% Cl 0.004-0.347)
De Rossi, 2020	Case-control	90/68	N/R	71 (15) ª	63 (13) ª	72	71	Tocilizumab group associated with reduced risk of mortality (aHR 0.057; 95% CI 0.017-0.187). Survival rate or mean time to discharge did not differ between two administration (IV and SC) routes.
Eimer, 2020	Case-control	22/22	30	60 (54-67) ^c	61 (49-64) ^c	77	96	No difference in all-cause mortality at 30 days (HR 0.52; 95% Cl 0.19- 1.39).Median time to death was 8 days in treated (IQR 5-12.5) and 14 days (IQR 10-19, p = 0.15) in control. In tocilizumab group, significantly more ventilator free days. Freedom from IMV was achieved earlier and in a higher proportion of patients (HR 2.83; 95% Cl 1.48-5.4). Length of hospital stay shorter in tocilizumab group
Galvan Roman, 2020	Case-control	58/88	61 (58-64) ^c	64 (54-72) ^b	61 (54-70) °	65	69	patients with high IL-6 not treated with TCZ showed high 139 mortality (HR: 4.6; p=0.003), as well as those with low IL-6 treated with tocilizumab (HR: 3.6; p=0.016).
Garcia, 2020	Case-control	77/94	14.7 (10.6) ª	61 (16) ^a	62 (12) ª	63	69	Tocilizumab associated with fewer ICU admissions (10.3% vs. 27.6%; p=0.005) and need for IMV (0 vs 13.8%, OR 0.03, 95% CI 0.007-0.1)
Gokhale, 2020	Case-control	70/91	31 (12-48) °	55 (48-65) ^c	52 (44-57) ^c	58	67	Tocilizumab associated with reduced mortality (HR 0.616;95% Cl 0.38-0.99)
Guaraldi, 2020	Case-control	179/365	12 (6-17) c	69 (57-78) ^c	64 (54-72) ^c	64	71	Tocilizumab use associated with reduced risk of death (7% vs. 20%; aHR 0.38; 95% CI 0.17-0.83) and composite outcome of IMV or death (aHR 0.61;95% CI 0.4-0.92).
Guisado- Vasco, 2020	Case-control	132/475	N/R	N/R	69 (22) ^c	N/R	65	Increased mortality with tocilizumab (aOR 2·4, 95% CI, 1·13 - 5·11)
Gupta, 2020	Case-control	433/3492	26 (15- 38) °	63 (52-72) °	58 (48-65) °	62	69	Patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92)

* Hill, 2020	Case-control	43/45	28	N/R	N/R	69	70	Tocilizumab not associated with lower risk of mortality (aHR 0.57; 95% Cl 0.21-1.52) or a difference in clinical improvement (aHR 0.92; 95% Cl 0.38-2.22)
Holt, 2020	Case-control	24/30	N/R	N/R	N/R	N/R	N/R	In multivariate analysis, tocilizumab administration had no effect on mortality (OR 0.32; 95% CI 0.02-3.69)
lp, 2020	Case-control	134/413	N/R	69 (58-77) ^c	62 (533-70) ^c	62	74	Tocilizumab associated with reduced mortality within the ICU setting (aHJR 0.76; 95% CI 0.57-1.00)
Kewan, 2020	Case-control	28/23	10 (6-17) c	70 (55-75) ^c	62 (53-71) ^c	48	71	Median time to clinical improvement in tocilizumab vs. no tocilizumab was 6.5 days (IQR 4-9) vs. 7 days (IQR 5-10) among all patients (HR 1.14; 95% CI 0.55-2.38). Shorter median length of hospital stay with tocilizumab. The median duration of vasopressor support and IMV were 2 days (IQR: 1·75 – 4·25 days) vs. 5 days (IQR: 4 – 8 days), p = 0.039, and 7 days (IQR: 4 – 14 days) vs. 10 days (IQR: 5 – 15 days) in tocilizumab vs. no tocilizumab cohorts, p = 0.11
* Kimmig, 2020	Case-control	54/57	N/R	62 (17) ^a	65 (14) ª	44	69	Tocilizumab was associated with higher risk of mortality (35.2% vs 19.3%, p=0.02)
Klopfenstein , 2020	Case-control	20/25	N/R	71 (15) ª	77 (11) ª	N/R	N/R	Death and/or ICU admissions higher in tocilizumab cohort vs control (72% vs 25%; p=0.002). No difference in death alone (25% vs 48%; p=0.0066)
Martinez- Sanz, 2020	Case-control	260/969	6 (3-9) °	68 (57-80) ^c	65 (55-76) ^c	59	73	In patients with CRP>150mg/L, tocilizumab associated with decreased risk of death (aHR 0.34; 95% CI 0.16-0.72) and ICU admission or death (aHR 0.38; 95% CI 0.19-0.81), but not in those with CRP <150mg/L. For all patients, tocilizumab not associated with risk of death (HR 1.53; 95% CI 1.2-1.96) or ICU/death (HR 1.77I; 95% CI 1.41-2.22)
*# Narain, 2020	Case-control	60/1505	N/R	65 (54-77) [°]	62 (55-70) ^c	62	75	No effect on mortality (aHR 0.72; 95% CI 0.4-1.28)
Patel, 2020	Case-control	42/41	19 (5.5) ^c	67 (20-91) ^b	68 (25-96) ^b	49	50	CRP improved in all tocilizumab patients. No difference in mortality with tocilizumab but more patients discharged compared with controls (55% vs 24%)

Pettit, 2020	Case-control	74/74	58	65 (16) ª	66 (14) ª	45	58	Mortality rate higher in tocilizumab cohort (39% vs 23%; p=0.03).
Potere, 2020	Case-control	10/10	N/R	56 (49-60) ^c	55 (54-60) ^c	60	60	Tocilizumab associated with reduction in CRP over three days. None of the tocilizumab patients had disease progression (requirement of oxygen or mechanical ventilation) whereas progression occurred in 50% of control group
*Ramaswam y, 2020	Case-control	21/65	N/R	64 (16) ^a	63 (16) ª	55	62	Mortality lower in tocilizumab group (HR 0.25; 95% Cl 0.07-0.9)
Rodriguez- Bano, 2020	Case-control	88/344	21	69 (59-76) [°]	66 (56-72) °	69	72	Tocilizumab associated with reduced risk of death (aHR 0.12; 95% Cl 0.02-0.56) and reduced risk of composite outcome of intubation or death (aHR 0.32; 95% Cl 0.15-0.67)
Rojas-Marte, 2020	Case-control	96/97	14.5 (8.8) ª	62 (14) ª	58 (14) ª	²65	77	Similar mortality in both groups (52% vs 61%; p=0.09)
Roomi, 2020	Case-control	32/144	N/R	66	58	45	64	No difference in hospital mortality (aOR 0.28; 95% CI 0.05-1.4), IMV (aOR 1.2;95% CI 0.49-2.9) and hospital discharge (aOR 0.78;95% CI 0.28-2.1). Reduction in CRP levels on day 7 compared with control (21% vs 56%; OR 0.21; 95% CI 0.08-0.55
* Rossi, 2020	Case-control	84/84	28	64 (17) ^a	65 (13)ª	58	66	Tocilizumab associated with reduced mortality (aHR 0.42; 95% CI 0.22-0.82), and reduced composite of mortality or IMV (aHR 0.49; 95% CI 0.3-0.81)
Rossotti, 2020	Case-control	74/148	N/R	59 (52-70) ^c	59 (51-71) °	81	82	Tocilizumab associated with reduced mortality (HR 0.49; 95% CI 0.26- 0.95), but longer hospital stay (HR 1.66; 95% CI 1.09-2.52)
* Roumier, 2020	Case-control	30/29	8 (6-10) ^c	71 (15) ª	59 (12) ª	79	80	Tocilizumab reduced requirement for IMV (OR 0.42; 95% Cl 0.2-0.89). No difference in mortality.
* Ruiz- Antoran, 2020	Case-control	268/238	12 (7-18) b	71 14) ª	65 (12) ^a	59	69	Mortality lower in patients treated with tocilizumab than controls (16.8% vs. 31.5%, HR 0.514; 95%Cl 0.355-0.744)

Somers, 2020	Case-control	78/76	N/R	60 (15) ª	55 (15) ª	64	68	Tocilizumab associated with lower risk of death (aHR 0.55; 95% Cl 0.33-0.9)
* Tsai, 2020	Case-control	66/66	N/R	61 (16) ª	62 (14) ª	76	70	No difference in mortality between two groups (OR 1.0;95% CI 0.465-2.151)
Zheng, 2020	Case-control	92/89	28 (6-62) b	67 (25-85) ^b	69 (25-87) ^b	53	62	Increased mortality in tocilizumab group, but significant reduction in CRP level at 1 week

Supplementary Table 2 – Patient characteristics and outcomes of included studies. Absolute numbers reported for follow up days unless otherwise statement. Number of males in control and intervention group reported as percentage (%)

^a, mean and standard deviation; ^b, median and range; ^c, median and interquartile range; aHR, adjusted hazard ratio; CI, confidence interval; CRP, C-reactive protein; ICU, intensive care unit; IL6, interleukin-6; IMV, invasive mechanical ventilation; IV, intravenous; N/R, not reported; OR, odds ratio; SC, subcutaneous; -, not available; * non peer-reviewed preprint study #, study investigating both anakinra and tocilizumab

Outcome	The GRADE domains	Ratings for quality of evidence
	Risk of bias	Of the 4 prospective included, 3 RCTs of low/moderate risk of bias included. Retrospective studies generally of fair quality, although cannot exclude failure to control confounding factors.
	Imprecision	No serious imprecision, with appropriately narrow 95% confidence intervals. Outcome based on 1782 patients.
Ordinal scale (12 studies; 4 prospective and 8 retrospective. Total of	Inconsistency	High inconsistency with significant heterogeneity in both prospective and retrospective studies.
1782 patients)	Indirectness	No serious indirectness. All studies included a control arm from the same population. All study subjects had Covid-19, although severity and participation criteria were inconsistent.
	Publication bias	No publication bias as indicated by funnel plots and Egger's tests
	Certainty of evidence	Moderate certainty of evidence.
	Risk of bias	All included studies with moderate/high risk of bias. Confounding factors were poorly controlled for.
	Imprecision	Serious imprecision, with studies showing shorter and longer duration of hospitalisation with tocilizumab. Appropriately narrow 95% confidence intervals. Outcome based on 446 patients.
Difference in duration of hospitalisation (8 retrospective studies.	Inconsistency	High inconsistency with significant heterogeneity ($I^2 = 85\%$).
Total of 446 patients)	Indirectness	No serious indirectness. All studies included a control arm from the same population. All study subjects had Covid-19, although severity and participation criteria were inconsistent.
	Publication bias	No publication bias as indicated by funnel plots and Egger's tests
	Certainty of evidence	Low certainty of evidence.

	Risk of bias	RCTs of low/moderate risk of bias included.
	Imprecision	Imprecision present as wide confidence intervals for prospective studies, in both RCTs and summary estimates, reporting adjusted HRs
Overall mortality (aHR - 17 studies. Total of 10,159	Inconsistency	High inconsistency in retrospective studies, but not in prospective studies.
patients. RR - 31 studies, 10,568 patients)	Indirectness	No serious indirectness. All studies included a control arm from the same population. All study subjects had Covid-19, although severity and participation criteria were inconsistent
	Publication bias	No publication bias as indicated by funnel plots and Egger's tests
	Certainty of evidence	Moderate certainty of evidence.

Supplementary Table 3 – GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach to rate the quality of evidence on the effects of tocilizumab

			Ret	rospective studies	5				
Variables		odds ratios for comes (N=8)		n duration of ation (N=6)	-	zard ratios for ty (N=14)	Risk ratios for mortality (N=26)		
	R ²	P value	R ²	P value	R ²	P value	R ²	P value	
Steroid use	0.00	0.7921	0.00	0.3882	0.00	0.3097	0.00	0.9813	
Peer review	0.00	0.5067	N/A	N/A	86.89	0.7388	0.35	0.3137	
Drug delivery	4.75	0.3526	94.37	p<0.001	0.00	0.3062	8.33	0.1146	
Single centre	0.00	0.6028	N/A	N/A	0.00	0.4138	0.00	0.6616	
Outcome day	0.00	0.7921	N/A	N/A	30.84	0.7910	30.37	0.013	
			Pro	ospective studies					
Variables	Generalised of	odds ratios for	Difference i	n duration of	Adjusted ha	zard ratios for	Risk ratios for	mortality (N=5)	
	ordinal out	comes (N=5)	hospitalis	ation (N=0)	mortal	ity (N=3)			
	R ²	P value	R ²	P value	R ²	P value	R ²	P value	
Steroid use	99.99	< 0.0001	N/A	N/A	93.3	0.7960	81.92	0.1819	
Peer review	0.00	0.4165	N/A	N/A	N/A	N/A	N/A	N/A	
Drug delivery	N/A	N/A	N/A	N/A	93.3	0.7960	99.62	0.3689	
Single centre	0.00	0.5332	N/A	N/A	93.3	0.7960	7.17	0.1677	
Outcome day	0.00	0.5351	N/A	N/A	11.3	0.9103	19.21	0.8795	

Supplementary Table 4 - Results of meta-regression for variables assessed separated by study design (retrospective and prospective) and study outcomes. Sample sizes for each outcome shown (N). R² and p values from meta-regression shown were applicable. N/A, not applicable.

Randomised controlled trials												
	Hermine 2020	Rosas 2020 *	Salvarani 2020	Stone 2020								
Randomisation	Low	Low	Low	Low								
Intervention assignment	High	Low	High	Low								
Intervention adherence	Some concern	Low	Some concern	Low								
Missing data	Low	Low	Low	Low								
Outcome	Low	Low	Low	Low								
Results	Low	Low	Low	Low								
Overall risk of bias	Some concern	Low	Some concern	Low								

Supplementary Table 5(a) – Risk of bias assessment for randomised clinical trials using Cochrane risk of bias 2 tool. Risk of bias was assessed in six categories and scored as either low risk of bias, some concern, or high risk of bias, before an overall risk of bias was given to each study.

* non peer-reviewed preprint study

							Prospect	ive studies					
							Tocil	izumab					
	Albertini 2020	Antony 2020	Campins 2020	Carvalo 2020 *	Dastan 2020	Malekzad eh, 2020	Mikulsa 2020	Morena 2020	Perrone 2020 *	Sanchez- Motalva 2020 *	Sciascia 2020	Strohbehn 2020 *	Toniati 2020
1	+	+	-	+	+	+	+	+	+	+	-	+	+
2	+	+	-	+	+	+	+	+	+	+	+	+	+
3	+	+	CD	CD	+	CD	+	+	+	+	CD	+	+
4	+	+	+	+	+	+	+	+	+	+	+	+	+
5	-	-	-	-	-	-	-	-	+	-	-	-	-
6	+	+	+	+	+	+	+	+	+	+	+	+	+
7	+	-	CD	+	+	+	+	+	+	+	+	+	+
8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
9	-	+	-	-	+	+	-	+	+	-	-	+	-
10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
11	+	-	-	+	+	+	+	+	+	+	+	+	-
12	-	-	-	-	-	-	-	-	-	-	-	-	-
13	+	+	CD	+	+	+	+	+	+	+	+	+	+
14	-	-	-	+	-	-	+	+	-	+	-	+	-
Total	8	7	2	8	9	8	9	10	10	9	6	10	7
Rating	Fair	Fair	Poor	Fair	Fair	Fair	Fair	Good	Good	Fair	Poor	Good	Fair

			Prospe	ctive studies			
	Anal	kinra		Sarilur	nab		Siltuximab
	Aouba 2020	Huet 2020	Benucci 2020	Della-Torre 2020	Sinha 2020	Gremese 2020	Gritti 2020 ⁻
1	+	+	+	+	+	+	+
2	+	+	-	+	+	+	+
3	CD	+	CD	+	+	+	+
4	+	+	-	+	+	+	+
5	-	+	-	-	-	-	-
6	+	+	+	+	+	+	+
7	+	CD	+	+	+	+	+
8	N/A	N/A	N/A	N/A	N/A	N/A	N/A
9	+	+	+	+	+	+	+
10	N/A	N/A	N/A	N/A	N/A	N/A	N/A
11	-	+	+	+	+	+	+
12	-	-	-	-	-	-	-
13	+	+	+	+	+	+	+
14	-	+	-	+	+	-	+
Total	7	10	6	10	10	9	10
Rating	Fair	Good	Poor	Good	Good	Fair	Good

Supplementary Table 5(b). Risk of bias assessment for prospective studies. Questions numbered in the first column. 1. Was the research question or objective in this paper clearly stated? 2. Was the study population clearly specified and defined? 3. Was the participation rate of eligible persons at least 50%? 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? 5. Was a sample size justification, power description, or variance and effect estimates provided? 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 10. Was the exposure(s) assessed more than once over time? 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? 12. Were the outcome assessors blinded to the exposure status of participants? 13. Was loss to follow-up after baseline 20% or less? 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

+, criteria satisfied; -, not satisfied; N/A, not applicable; CD, cannot determine; * non peer-reviewed preprint study

								Ca	se-contro	studies									
										Тос	ilizumab	1							
	Biran 2020	Canziani 2020	Capra 2020	De Rossi 2020	Eimer 2020	Galvan- Roman 2020	Gokhale 2020	Guaraldi 2020	Guisado- Vasco 2020	Gupta 2020	Hill 2020 *	Holt 2020	lp 2020	Kewan 2020	Kimmig 2020 *	Klopfenst ein 2020	Martinez- Sanz 2020	Moreno- Garcia 2020 *	Narain, 2020 *
1	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
2	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
3	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	+	+	+	+	+	+	+	+	+	+	+	CD	+	+	+	+	+	+	+
5	+	+	+	+	-	CD	+	-	+	+	-	CD	+	-	CD	-	-	-	+
6	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+
7	+	+	+	+	+	CD	+	+	+	+	+	CD	+	+	+	+	+	+	+
8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
10	-	-	-	-	+	+	+	-	-	+	-	+	+	+	-	-	-	+	-
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	-	+	-	+
Total	8	8	9	9	7	6	8	7	7	9	7	6	9	8	7	6	7	7	8
Rating	Fair	Fair	Good	Good	Fair	Fair	Fair	Fair	Fair	Good	Fair	Fair	Good	Fair	Fair	Poor	Fair	Fair	Fair

								(Case-contro	ol studies										
									Tocilizu	ımab						Anakinra				
	Patel 2020	Pettit 2020	Potere 2020	Ramas wamy 2020 *	Rodriguez- Bano 2020	Rojas- Marte 2020	Roomi 2020	Rossi 2020 *	Rossotti 2020	Roumier 2020 *	Ruiz- Antoran 2020 *	Somers 2020	Tsai 2020 *	Wadud 2020 *	Zheng 2020	Cauchois 2020	Cavalli 2020	Narain 2020 *		
1	+	+	+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	+		
2	-	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+		
3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
4	+	+	+	+	+	+	CD	+	+	CD	+	+	+	+	CD	+	+	+		
5	-	+	+	+	+	CD	-	+	+	CD	CD	CD	+	-	-	+	+	+		
6	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
7	+	+	+	+	+	CD	CD	+	+	+	+	CD	+	CD	CD	+	+	+		
8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
9	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
10	CD	-	+	+	CD	CD	-	+	+	+	-	+	-	-	+	+	+	-		
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
12	-	-	-	+	+	-	+	+	+	-	+	+	+	-	-	-	-	+		
Total	5	7	8	9	8	4	4	9	9	6	7	7	7	3	5	8	8	8		
Rating		Fair	Fair	Good	Fair	Poor	Poor	Good	Good	Fair	Fair	Fair	Fair	Poor	Poor	Fair	Fair	Fair		

Supplementary Table 5(c). Risk of bias assessment for case-control studies. 1. Was the research question or objective in this paper clearly stated and appropriate? 2. Was the study population clearly specified and defined? 3. Did the authors include a sample size justification? 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? 6. Were the cases clearly defined and differentiated from controls? 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? 8. Was there use of concurrent controls? 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? 11. Were the assessors of exposure/risk blinded to the case or control status of participants? 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?

+, criteria satisfied; -, not satisfied; N/A, not applicable; CD, cannot determine; * non peer-reviewed preprint study